RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Marketable securities, current

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndMarketable securities, current (Million USD)YoY (%)
Dec 31, 20246,524-19.60%
Dec 31, 20238,115+75.02%
Dec 31, 20224,636+65.05%
Dec 31, 20212,809+101.61%
Dec 31, 20201,393-12.73%
Dec 31, 20191,597+18.95%
Dec 31, 20181,342+124.90%
Dec 31, 2017597+18.53%
Dec 31, 2016503+113.23%
Dec 31, 2015236-6.21%
Dec 31, 2014252+58.96%
Dec 31, 2013158+103.52%
Dec 31, 201278+79.59%
Dec 31, 201143-68.32%
Dec 31, 2010137

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)